Abstract
For many years, there has been an ongoing search for new compounds that can selectively alter gene expression as a new way to treat human disease by addressing targets that are otherwise “undruggable” with traditional pharmaceutical approaches involving small molecules or proteins. RNA interference (RNAi) strategies have raised a lot of attention and several compounds are currently being tested in clinical trials. Viruses are the obvious target for RNAitherapy, as most are difficult to treat with conventional drugs, they become rapidly resistant to drug treatment and their genes differ substantially from human genes, minimizing side effects. Antisense strategy offers very high target specificity, i.e., any viral sequence could potentially be targeted using the complementary oligonucleotide sequence. Consequently, new antisense-based therapeutics have the potential to lead a revolution in the anti-infective drug development field. Additionally, the relatively short turnaround for efficacy testing of potential RNAi molecules and that any pathogen is theoretically amenable to rapid targeting, make them invaluable tools for treating a wide range of diseases. This review will focus on some of the current efforts to treat infectious disease with RNAi-based therapies and some of the obstacles that have appeared on the road to successful clinical intervention.
Keywords: RNAi, infectious disease, siRNA, antiviral, therapy
Infectious Disorders - Drug Targets
Title: RNA Interference-Based Therapeutics: New Strategies to Fight Infectious Disease
Volume: 8 Issue: 4
Author(s): M. Lopez-Fraga, N. Wright and A. Jimenez
Affiliation:
Keywords: RNAi, infectious disease, siRNA, antiviral, therapy
Abstract: For many years, there has been an ongoing search for new compounds that can selectively alter gene expression as a new way to treat human disease by addressing targets that are otherwise “undruggable” with traditional pharmaceutical approaches involving small molecules or proteins. RNA interference (RNAi) strategies have raised a lot of attention and several compounds are currently being tested in clinical trials. Viruses are the obvious target for RNAitherapy, as most are difficult to treat with conventional drugs, they become rapidly resistant to drug treatment and their genes differ substantially from human genes, minimizing side effects. Antisense strategy offers very high target specificity, i.e., any viral sequence could potentially be targeted using the complementary oligonucleotide sequence. Consequently, new antisense-based therapeutics have the potential to lead a revolution in the anti-infective drug development field. Additionally, the relatively short turnaround for efficacy testing of potential RNAi molecules and that any pathogen is theoretically amenable to rapid targeting, make them invaluable tools for treating a wide range of diseases. This review will focus on some of the current efforts to treat infectious disease with RNAi-based therapies and some of the obstacles that have appeared on the road to successful clinical intervention.
Export Options
About this article
Cite this article as:
Lopez-Fraga M., Wright N. and Jimenez A., RNA Interference-Based Therapeutics: New Strategies to Fight Infectious Disease, Infectious Disorders - Drug Targets 2008; 8 (4) . https://dx.doi.org/10.2174/187152608786734223
DOI https://dx.doi.org/10.2174/187152608786734223 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Infectious Causes of Childhood Disability
Infectious Disorders - Drug Targets Protein Conformational Pathology in Alzheimers and Other Neurodegenerative Diseases; New Targets for Therapy
Current Alzheimer Research Helminth Infections and Cardiovascular Diseases: Toxocara Species is Contributing to the Disease
Current Cardiology Reviews Regulatory T Cells and Allergic Disease
Inflammation & Allergy - Drug Targets (Discontinued) Immuno - Functionalized Silver Nanoparticles for Diagnostics, Therapeutics and Protection of Rabies Viral Infection
Current Nanomedicine Inhibition of West Nile virus Replication by Bifunctional siRNA Targeting the NS2A and NS5 Conserved Region
Current Gene Therapy Dementia Etiologies and Remedies in Traditional Persian Medicine; A Review of Medicinal Plants and Phytochemistry
Current Drug Metabolism Virus Vasculopathy and Stroke: An Under-Recognized Cause and Treatment Target
Infectious Disorders - Drug Targets Editorial: “Phytochemicals for Human Diseases: An Update”
Current Drug Targets Immunopathological Aspects of Mycoplasma pneumoniae Infection
Current Pediatric Reviews A New Interpretative Paradigm for Conformational Protein Diseases
Current Protein & Peptide Science Neonatal Fever in the Term Infant: Evaluation and Management Strategies
Current Pediatric Reviews Manipulation of Dendritic Cells for Tumor Immunity
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Disease-Induced Neuroinflammation and Depression
CNS & Neurological Disorders - Drug Targets Recent Advances on Immunosuppressive Drugs and Remyelination Enhancers for the Treatment of Multiple Sclerosis
Current Pharmaceutical Design Vaccine-Associated Neurological Adverse Events: A Case Report and Literature Review
Current Pharmaceutical Design Disease Modifying Therapeutic Strategies in Alzheimers Disease Targeting the Amyloid Cascade
Current Neuropharmacology Gut-brain Axis: Role of Lipids in the Regulation of Inflammation, Pain and CNS Diseases
Current Medicinal Chemistry Penetration and Effectiveness of Antiretroviral Therapy in the Central Nervous System
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Silkworm as a Host of Baculovirus Expression
Current Pharmaceutical Biotechnology